Allogene Therapeutics, Inc.
ALLO
Biological Products, (No Diagnostic Substances)
Mkt Cap
$411MPE
-0.27Debt
-Cash
$61.33MEV
-FCF
-$227.5MP/E Ratio
-0.27Debt
-Cash
$61.33MEV
-FCF
-$227.5MCharts data: {"Earnings":[{"time":"2017-12-30","value":-2000},{"time":"2018-12-30","value":-211505000},{"time":"2019-12-30","value":-396100000},{"time":"2020-12-30","value":-646300000},{"time":"2021-12-30","value":-903300000},{"time":"2022-12-30","value":-1236000000},{"time":"2023-12-30","value":-1562200000}],"Sales":[{"time":"2019-12-30","value":0},{"time":"2020-12-30","value":0},{"time":"2021-12-30","value":38489000},{"time":"2022-12-30","value":243000},{"time":"2023-12-30","value":95000}],"Net Margins":[{"time":"2021-12-30","value":-23.469043103224298},{"time":"2022-12-30","value":-5086.419753086419},{"time":"2023-12-30","value":-16444.21052631579}],"Assets":[{"time":"2018-12-30","value":773855000},{"time":"2019-12-30","value":717802000},{"time":"2020-12-30","value":1227829000},{"time":"2021-12-30","value":1038634000},{"time":"2022-12-30","value":817079000},{"time":"2023-12-30","value":642837000}],"Stockholders Equity":[{"time":"2017-12-30","value":-2000},{"time":"2018-12-30","value":703164000},{"time":"2019-12-30","value":629023000},{"time":"2020-12-30","value":1079617000},{"time":"2021-12-30","value":916406000},{"time":"2022-12-30","value":665870000},{"time":"2023-12-30","value":512233000}],"ROE":[{"time":"2017-12-30","value":1},{"time":"2018-12-30","value":-0.3007904272687453},{"time":"2019-12-30","value":-0.6297067038884111},{"time":"2020-12-30","value":-0.598638220776442},{"time":"2021-12-30","value":-0.9856984786219208},{"time":"2022-12-30","value":-1.8562181807259674},{"time":"2023-12-30","value":-3.049783985022441}],"ROA":[{"time":"2018-12-30","value":-0.24919655491015757},{"time":"2019-12-30","value":-0.25762675501043464},{"time":"2020-12-30","value":-0.2037914074354002},{"time":"2021-12-30","value":-0.24627732194401492},{"time":"2022-12-30","value":-0.41054659341385596},{"time":"2023-12-30","value":-0.5098290857557981}]}
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Sector
In the chart Earnings are multiplied by this value.
Earnings Growth -
Earnings Stability -
Competitiveness and MOAT
High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.
| Years | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
|---|---|---|---|---|---|---|---|---|
| Net Margin | - | - | - | - | -2.3K% | -510K% | -1.6M% | -2.4M% |
| ROA | - | -25% | -26% | -20% | -25% | -41% | -51% | -51% |
| ROE | 100% | -30% | -63% | -60% | -99% | -190% | -300% | -330% |
What is the average Net Margin?
The average Net Margin over the past 5 years is -718.47K%.
What is the trend of Net Margin?
The trend of Net Margin over the past 5 years is -821.04K%.
What is the average Return on Assets (ROA)?
The average ROA over the past 5 years is -31.29%.
What is the trend of Return on Assets (ROA)?
The trend of ROA over the past 5 years is -5.16%.
What is the average Return on Equity (ROE)?
The average ROE over the past 5 years is -123.68%.
What is the trend of Return on Equity (ROE)?
The trend of ROE over the past 5 years is -50.89%.
Safety & Stabiliy
Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.
| Years | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Debt FCF | - | - | - | - | - | - | - | - | ||
| Debt Equity | - | - | - | - | - | - | - | - | ||
| MIN | ||||||||||
| Graham Stability | - | - | - | - | - | - | - | - | ||
What is the Debt/FCF?
The Debt/FCF trailing twelve month is -.
What is the trend of Debt/FCF?
The trend of Debt/FCF over the past 5 years is -.
What is the Graham’s Stability?
Graham’s Stability measure stands at -.
Growth
Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.
| Years | 12-2018 | 12-2020 | 12-2022 | Trend |
|---|---|---|---|---|
| Revenue | - | - | -61% | 38% |
| Net Income | - | - | - | - |
| Stockholders Equity | -6.1% | -22% | -23% | -12% |
| FCF | - | - | - | - |
What is the 5 year Revenue CAGR?
The Revenue CAGR over the past 5 years is -.
What is the trend of Revenue growth?
The trend of Revenue growth rate over the past 5 years is +38.46%.
What is the 5 year Earnings CAGR?
The Earnings CAGR over the past 5 years is +49.17%.
What is the trend of Earnings growth?
The trend of Earnings growth rate over the past 5 years is -.
What is the 5 year Equity CAGR?
The Equity CAGR over the past 5 years is -6.14%.
What is the trend of Equity growth?
The trend of Equity growth rate over the past 5 years is -12.4%.
What is the 5 year FCF CAGR?
The FCF CAGR over the past 5 years is +37.95%.
What is the trend of FCF growth?
The trend of FCF growth rate over the past 5 years is -.